Biotech Cos. Rise as Gov\'t OKs New Stem Cell Lines

Primary tabs

By MATTHEW PERRONE - The Associated Press

WASHINGTON — Shares of companies developing stem cell therapies surged Wednesday on news that the federal government has cleared 13 new stem cell lines for testing, bringing to a close nearly a decade of restrictions.

"For the first time all these programs that have been held in check by the closed stem cell policy can move forward," said Steve Brozak, president and analyst with WBB Securities, an investment brokerage focused on drug and biotech companies.

Read full article


  • Workflow Status: Published
  • Created By: Colly Mitchell
  • Created: 12/03/2009
  • Modified By: Fletcher Moore
  • Modified: 10/07/2016

Target Audience

No target audience selected.